Wallstreetcn reported that Moderna and Merck's personalized mRNA cancer vaccine, Intismeran Autogene (mRNA-4157/V940), administered with the PD-1 inhibitor pembrolizumab, reached positive Phase 3 results in melanoma.

In the trial, both recurrence-free survival and distant metastasis-free survival met the key endpoints set for the study.